Published • loading... • Updated
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Nine U.S. doctors said lower-priced branded pills are drawing patients from compounded versions as insurance coverage stays uneven.
- Lower-Priced oral GLP-1 pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to interviews with nine U.S. doctors.
- With supply shortages of branded drugs now eased, the Food and Drug Administration is tightening limits on compounded GLP-1 formulations to steer patients toward FDA-approved treatments subject to greater oversight.
- Oral Wegovy led to about a 14% weight reduction over 64 weeks, while Foundayo showed an 11% reduction over 72 weeks in separate studies; both pills cost around $149 monthly.
- Dr. Jorge Moreno, a Yale Medicine Obesity Specialist, noted that "something about saying it is new creates a little hesitation" in some patients, while insurance coverage remains a persistent challenge for many.
- Two of the three largest U.S. pharmacy benefit managers now cover Foundayo, and a government program providing GLP-1 coverage to Medicare patients is set to begin in July and run through 2027.
Insights by Ground AI
7 Articles
7 Articles
FOCUS-Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions. As many patients struggle with declining insurance coverage, the lower-priced options have been a boon for the drugmakers, the doctors said.
·India
Read Full Article
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U.S. doctors.
·United Kingdom
Read Full ArticleCoverage Details
Total News Sources7
Leaning Left0Leaning Right2Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
C 71%
R 29%
Factuality
To view factuality data please Upgrade to Premium
